<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359254</url>
  </required_header>
  <id_info>
    <org_study_id>10-020-B</org_study_id>
    <nct_id>NCT01359254</nct_id>
  </id_info>
  <brief_title>Cord Blood Transplantation for Patients With Cancer</brief_title>
  <official_title>Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the rate of engraftment with combined
      haploidentical-cord blood transplantation in patients with pre-existing donor specific
      antibodies and in those with active disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective

      - To assess the rate of engraftment with combined haploidentical-cord blood transplantation
      in patients with pre-existing donor specific anti-HLA antibodies and in those with active
      disease

      Secondary Objectives

        -  To determine the long term fate of the haplo transplant and the cord blood transplant in
           this setting.

        -  To describe the incidence and severity of acute and chronic GVHD.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    did not accrue enough patients.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cord Blood Engraftment by Day 100</measure>
    <time_frame>100 days</time_frame>
    <description>Percent of subjects with cord blood engraftment on or before day 100. Detectable cord blood engraftment should be present by day 100 in at least 50% of patients.
As of 44 days post-transplant, only haploidentical donor chimerism achieved in the one patient enrolled in the Fludarabine, melphalan, and ATG arm. There were no cord cells detected for this patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival at Day 100</measure>
    <time_frame>100 days</time_frame>
    <description>Percent of subjects who are alive 100 days after the stem cell infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hematological Disease</condition>
  <arm_group>
    <arm_group_label>Conditioning Regimen I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning Regimen II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.</description>
    <arm_group_label>Conditioning Regimen I</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine is given through the vein daily for 5 days.</description>
    <arm_group_label>Conditioning Regimen I</arm_group_label>
    <arm_group_label>Conditioning Regimen II</arm_group_label>
    <other_name>fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte Globulin (ATG)</intervention_name>
    <description>ATG is given every other day for 4 days.</description>
    <arm_group_label>Conditioning Regimen I</arm_group_label>
    <arm_group_label>Conditioning Regimen II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan is given daily for 4 days.</description>
    <arm_group_label>Conditioning Regimen II</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Busulfex IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>TBI is given twice on the last day.</description>
    <arm_group_label>Conditioning Regimen II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory acute leukemia (myeloid or lymphoid)

          -  Acute leukemia in first remission at high-risk for recurrence

          -  Chronic myelogenous leukemia in accelerated phase or blast-crisis

          -  Chronic myelogenous leukemia in chronic phase

          -  Recurrent or refractory malignant lymphoma or Hodgkin lymphoma

          -  Chronic lymphocytic leukemia, relapsed or with poor prognostic features

          -  Multiple myeloma

          -  Myelodysplastic syndrome

          -  Chronic myeloproliferative disease

          -  Hemoglobinopathies

          -  Aplastic anemia

        Exclusion Criteria:

          -  Zubrod performance status &gt; 2

          -  Life expectancy is severely limited by concomitant illness

          -  Patients with severely decreased LVEF or impaired pulmonary function tests

          -  Estimated Creatinine Clearance &lt;50 ml/min

          -  Serum bilirubin&gt; 2.0 mg/dl or SGPT &gt;3 x upper limit of normal

          -  Evidence of chronic active hepatitis or cirrhosis

          -  HIV-positive

          -  Patient is pregnant

          -  Patient or guardian not able to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Artz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <results_first_submitted>April 10, 2015</results_first_submitted>
  <results_first_submitted_qc>April 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2015</results_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine, Melphalan, and ATG</title>
          <description>Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
Melphalan: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.</description>
        </group>
        <group group_id="P2">
          <title>Fludarabine, Busulfan, ATG, and TBI</title>
          <description>Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.
Busulfan: Busulfan is given daily for 4 days.
Total Body Irradiation (TBI): TBI is given twice on the last day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine, Melphalan, and ATG</title>
          <description>Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
Melphalan: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.</description>
        </group>
        <group group_id="B2">
          <title>Fludarabine, Busulfan, ATG, and TBI</title>
          <description>Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.
Busulfan: Busulfan is given daily for 4 days.
Total Body Irradiation (TBI): TBI is given twice on the last day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cord Blood Engraftment by Day 100</title>
        <description>Percent of subjects with cord blood engraftment on or before day 100. Detectable cord blood engraftment should be present by day 100 in at least 50% of patients.
As of 44 days post-transplant, only haploidentical donor chimerism achieved in the one patient enrolled in the Fludarabine, melphalan, and ATG arm. There were no cord cells detected for this patient.</description>
        <time_frame>100 days</time_frame>
        <population>The only enrolled patient failed to complete the study due to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine, Melphalan, and ATG</title>
            <description>Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
Melphalan: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine, Busulfan, ATG, and TBI</title>
            <description>Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.
Busulfan: Busulfan is given daily for 4 days.
Total Body Irradiation (TBI): TBI is given twice on the last day.</description>
          </group>
        </group_list>
        <measure>
          <title>Cord Blood Engraftment by Day 100</title>
          <description>Percent of subjects with cord blood engraftment on or before day 100. Detectable cord blood engraftment should be present by day 100 in at least 50% of patients.
As of 44 days post-transplant, only haploidentical donor chimerism achieved in the one patient enrolled in the Fludarabine, melphalan, and ATG arm. There were no cord cells detected for this patient.</description>
          <population>The only enrolled patient failed to complete the study due to death.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival at Day 100</title>
        <description>Percent of subjects who are alive 100 days after the stem cell infusion</description>
        <time_frame>100 days</time_frame>
        <population>The only enrolled patient failed to complete the study due to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine, Melphalan, and ATG</title>
            <description>Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
Melphalan: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine, Busulfan, ATG, and TBI</title>
            <description>Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.
Busulfan: Busulfan is given daily for 4 days.
Total Body Irradiation (TBI): TBI is given twice on the last day.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at Day 100</title>
          <description>Percent of subjects who are alive 100 days after the stem cell infusion</description>
          <population>The only enrolled patient failed to complete the study due to death.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>100 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine, Melphalan, and ATG</title>
          <description>Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
Melphalan: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.</description>
        </group>
        <group group_id="E2">
          <title>Fludarabine, Busulfan, ATG, and TBI</title>
          <description>Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
Fludarabine: Fludarabine is given through the vein daily for 5 days.
Antithymocyte Globulin (ATG): ATG is given every other day for 4 days.
Busulfan: Busulfan is given daily for 4 days.
Total Body Irradiation (TBI): TBI is given twice on the last day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Artz, MD, MS</name_or_title>
      <organization>The University of Chicago Medicine</organization>
      <phone>(773) 834-8980</phone>
      <email>aartz@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

